Benitec Biopharma (BNTC) Accumulated Expenses (2019 - 2025)

Benitec Biopharma has reported Accumulated Expenses for 7 years, with the latest figure at $483000.0 in Q4 2025.

• Quarterly Accumulated Expenses fell 10.06% year-over-year to $483000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $483000.0 (down 10.06% YoY) and the FY2025 annual result came in at $426000.0, down 10.32% from the prior year.
• Accumulated Expenses rose to $483000.0 in Q4 2025 per BNTC's latest filing, from $463000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.5 million in Q1 2023 and troughed at $231000.0 in Q1 2021.
• A 5-year average of $744000.0 and a median of $479000.0 in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 471.43% in 2022, then slumped 78.94% in 2024.
• Over 5 years, Accumulated Expenses stood at $321000.0 in 2021, then soared by 470.09% to $1.8 million in 2022, then sank by 71.42% to $523000.0 in 2023, then gained by 2.68% to $537000.0 in 2024, then decreased by 10.06% to $483000.0 in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $483000.0, $463000.0, and $426000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.